Somatuline Autogel is a prescription medication primarily used in the treatment of acromegaly, a condition characterized by the excessive production of growth hormone, and certain types of neuroendocrine tumors. The active ingredient in Somatuline Autogel is lanreotide, which is a synthetic analogue of somatostatin, a natural inhibitor of growth hormone. Lanreotide works by mimicking the action of somatostatin, thereby reducing the levels of growth hormone and insulin-like growth factor 1 (IGF-1) in the body. This medication is administered through a deep subcutaneous injection, typically once every 4 weeks, although the frequency and dosage may vary based on the patient's condition and response to treatment. Somatuline Autogel is noted for its extended-release formulation, which allows for less frequent dosing and a more consistent control of symptoms.